卡博替尼-话题@MedSci

#卡博替尼#

6篇内容 | 1150人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2196742, encodeId=304b2196e428a, content=<a href='/topic/show?id=32af9938ec6' target=_blank style='color:#2F92EE;'>#非小细胞肺癌#</a> <a href='/topic/show?id=f38743453f7' target=_blank style='color:#2F92EE;'>#多西他赛#</a> <a href='/topic/show?id=01a536491b9' target=_blank style='color:#2F92EE;'>#卡博替尼#</a> <a href='/topic/show?id=6bf49e844e9' target=_blank style='color:#2F92EE;'>#阿替利珠单抗#</a>, objectTitle=JCO：阿替利珠单抗联合卡博替尼或多西他赛用于既往免疫治疗和化疗后晚期非小细胞肺癌的III期临床试验, objectType=article, longId=820040, objectId=7c4782004028, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240402/1712066307729_6145188.png, objectUrl=/article/show_article.do?id=7c4782004028, replyNumber=0, likeNumber=18, createdTime=2024-04-03, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=7c4782004028, moduleTitle=JCO：阿替利珠单抗联合卡博替尼或多西他赛用于既往免疫治疗和化疗后晚期非小细胞肺癌的III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7c4782004028)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2188876, encodeId=c29f21888e6a1, content=<a href='/topic/show?id=493ae869206' target=_blank style='color:#2F92EE;'>#结直肠癌#</a> <a href='/topic/show?id=01a536491b9' target=_blank style='color:#2F92EE;'>#卡博替尼#</a> <a href='/topic/show?id=7b2910612398' target=_blank style='color:#2F92EE;'>#度伐利尤单抗#</a>, objectTitle=Nat. Commun：卡博替尼和度伐利尤单抗联合治疗化疗难治性结直肠癌（CRC）患者的Ⅱ期试验的临床和生物标志物结果：CAMILLA CRC队列, objectType=article, longId=814336, objectId=d1a8814336cc, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240222/1708616015635_6145188.png, objectUrl=/article/show_article.do?id=d1a8814336cc, replyNumber=0, likeNumber=25, createdTime=2024-02-23, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=d1a8814336cc, moduleTitle=Nat. Commun：卡博替尼和度伐利尤单抗联合治疗化疗难治性结直肠癌（CRC）患者的Ⅱ期试验的临床和生物标志物结果：CAMILLA CRC队列, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d1a8814336cc)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2184488, encodeId=7676218448832, content=<a href='/topic/show?id=3cc88658264' target=_blank style='color:#2F92EE;'>#舒尼替尼#</a> <a href='/topic/show?id=01a536491b9' target=_blank style='color:#2F92EE;'>#卡博替尼#</a> <a href='/topic/show?id=fc2be734870' target=_blank style='color:#2F92EE;'>#纳武利尤单抗#</a> <a href='/topic/show?id=c193110640f1' target=_blank style='color:#2F92EE;'>#ASCO GU 2024#</a>, objectTitle=ASCO GU 2024：纳武利尤单抗/卡博替尼治疗晚期肾癌优于舒尼替尼（CheckMate-9ER 研究）, objectType=article, longId=811384, objectId=440881138441, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240128/1706443016945_8624274.png, objectUrl=/article/show_article.do?id=440881138441, replyNumber=0, likeNumber=0, createdTime=2024-01-28, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=440881138441, moduleTitle=ASCO GU 2024：纳武利尤单抗/卡博替尼治疗晚期肾癌优于舒尼替尼（CheckMate-9ER 研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=440881138441)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2126279, encodeId=66ba21262e96c, content=基于STATs磷酸化诱导TAMs重塑探究<a href='/topic/show?id=2bbf10319ec5' target=_blank style='color:#2F92EE;'>#黄芪多糖#</a>协同<a href='/topic/show?id=01a536491b9' target=_blank style='color:#2F92EE;'>#卡博替尼#</a>抗<a href='/topic/show?id=97b783362ae' target=_blank style='color:#2F92EE;'>#胃肠间质瘤#</a>耐药机制 , objectTitle=基于STATs磷酸化诱导TAMs重塑探究黄芪多糖协同卡博替尼抗胃肠间质瘤耐药机制, objectType=nsfc, longId=1044299, objectId=b11f104429993, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/sci/nsfc_show.do?id=b11f104429993, replyNumber=0, likeNumber=52, createdTime=2023-04-16, rootId=0, userName=侠胆医心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=香港, moduleDTOList=[ModuleDTO(moduleId=b11f104429993, moduleTitle=基于STATs磷酸化诱导TAMs重塑探究黄芪多糖协同卡博替尼抗胃肠间质瘤耐药机制, moduleType=nsfc, hrefUrl=https://www.medsci.cn/sci/nsfc_show.do?id=b11f104429993)], followStatus=false, userIsMember=true, type=1, lengthMark=0), GetTopicListResponse(id=1242616, encodeId=f5a01242616dd, content=<a href='/topic/show?id=01a536491b9' target=_blank style='color:#2F92EE;'>#卡博替尼#</a>联合<a href='/topic/show?id=a4c810464e3c' target=_blank style='color:#2F92EE;'>#阿托珠单抗#</a>治疗<a href='/topic/show?id=a17393408d0' target=_blank style='color:#2F92EE;'>#转移性去势抵抗性前列腺癌#</a>, objectTitle=Lancet Oncol：卡博替尼联合阿托珠单抗治疗转移性去势抵抗性前列腺癌, objectType=article, longId=729045, objectId=c007e2904512, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20220609/1654778521483_2110107.PNG, objectUrl=/article/show_article.do?id=c007e2904512, replyNumber=0, likeNumber=52, createdTime=2022-09-02, rootId=0, userName=循证小兵, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c007e2904512, moduleTitle=Lancet Oncol：卡博替尼联合阿托珠单抗治疗转移性去势抵抗性前列腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c007e2904512)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1241529, encodeId=9851124152909, content=<a href='/topic/show?id=cbf69352875' target=_blank style='color:#2F92EE;'>#软组织肉瘤#</a><a href='/topic/show?id=01a536491b9' target=_blank style='color:#2F92EE;'>#卡博替尼#</a>, objectTitle=Clin Cancer Res：采用卡博替尼单药治疗晚期软组织肉瘤, objectType=article, longId=294798, objectId=9a57294e98ea, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2022126/1643202894785_2110107.JPG, objectUrl=/article/show_article.do?id=9a57294e98ea, replyNumber=0, likeNumber=0, createdTime=2022-08-28, rootId=0, userName=循证小兵, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9a57294e98ea, moduleTitle=Clin Cancer Res：采用卡博替尼单药治疗晚期软组织肉瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9a57294e98ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=918331, encodeId=b144918331eb, content=<a href='/topic/show?id=01a536491b9' target=_blank style='color:#2F92EE;'>#卡博替尼#</a>卡博替尼作为靶向药对晚期肝癌疗效理想。, objectTitle=卡博替尼, objectType=topic, longId=36491, objectId=null, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=null, replyNumber=0, likeNumber=64, createdTime=2021-01-20, rootId=0, userName=yangchou, userId=88b489038, projectId=1, avatar=, status=1, hasArticle=0, attachment=null, ipAttribution=, moduleDTOList=null, followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=914980, encodeId=781091498052, content=<a href='/topic/show?id=3325955142f' target=_blank style='color:#2F92EE;'>#酪氨酸激酶抑制剂#</a>&<a href='/topic/show?id=01a536491b9' target=_blank style='color:#2F92EE;'>#卡博替尼#</a>, objectTitle=J Gastroenterol：多靶点小分子酪氨酸激酶抑制剂卡博替尼可有效治疗晚期肝癌, objectType=article, longId=205516, objectId=f6672055161a, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202118/1610065602403_1739456.jpg, objectUrl=/article/show_article.do?id=f6672055161a, replyNumber=0, likeNumber=0, createdTime=2021-01-09, rootId=0, userName=zb1235672, userId=59321624668, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f6672055161a, moduleTitle=J Gastroenterol：多靶点小分子酪氨酸激酶抑制剂卡博替尼可有效治疗晚期肝癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f6672055161a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=802689, encodeId=c6a4802689fd, content=<a href='/topic/show?id=01a536491b9' target=_blank style='color:#2F92EE;'>#卡博替尼#</a>肿瘤治疗的第三道防线。, objectTitle=Lancet oncol：卡博替尼用于铂耐药的转移性尿路上皮癌的临床活性, objectType=article, longId=197427, objectId=6caa19e42798, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/1280x720_scitoc_jun03_R1.jpg, objectUrl=/article/show_article.do?id=6caa19e42798, replyNumber=0, likeNumber=127, createdTime=2020-07-13, rootId=0, userName=lovetcm, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6caa19e42798, moduleTitle=Lancet oncol：卡博替尼用于铂耐药的转移性尿路上皮癌的临床活性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6caa19e42798)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

卡博替尼

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#非小细胞肺癌# #多西他赛# #卡博替尼# #阿替利珠单抗#

JCO：阿替利珠单抗联合卡博替尼或多西他赛用于既往免疫治疗和化疗后晚期非小细胞肺癌的III期临床试验

2024-04-03发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#结直肠癌# #卡博替尼# #度伐利尤单抗#

Nat. Commun：卡博替尼和度伐利尤单抗联合治疗化疗难治性结直肠癌（CRC）患者的Ⅱ期试验的临床和生物标志物结果：CAMILLA CRC队列

2024-02-23发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#舒尼替尼# #卡博替尼# #纳武利尤单抗# #ASCO GU 2024#

ASCO GU 2024：纳武利尤单抗/卡博替尼治疗晚期肾癌优于舒尼替尼（CheckMate-9ER 研究）

2024-01-28发表于上海

(审核中...)

前往app查看评论内容

基于STATs磷酸化诱导TAMs重塑探究#黄芪多糖#协同#卡博替尼#抗#胃肠间质瘤#耐药机制

基于STATs磷酸化诱导TAMs重塑探究黄芪多糖协同卡博替尼抗胃肠间质瘤耐药机制

2023-04-16发表于香港

循证小兵 (审核中...)

前往app查看评论内容

#卡博替尼#联合#阿托珠单抗#治疗#转移性去势抵抗性前列腺癌#

Lancet Oncol：卡博替尼联合阿托珠单抗治疗转移性去势抵抗性前列腺癌

2022-09-02

循证小兵 (审核中...)

前往app查看评论内容

#软组织肉瘤##卡博替尼#

Clin Cancer Res：采用卡博替尼单药治疗晚期软组织肉瘤

2022-08-28

yangchou (审核中...)

前往app查看评论内容

#卡博替尼#卡博替尼作为靶向药对晚期肝癌疗效理想。

2021-01-20

zb1235672 (审核中...)

前往app查看评论内容

#酪氨酸激酶抑制剂#&#卡博替尼#

J Gastroenterol：多靶点小分子酪氨酸激酶抑制剂卡博替尼可有效治疗晚期肝癌

2021-01-09

lovetcm (审核中...)

前往app查看评论内容

#卡博替尼#肿瘤治疗的第三道防线。

Lancet oncol：卡博替尼用于铂耐药的转移性尿路上皮癌的临床活性

2020-07-13

科室
- - 订阅+
  - 更多科室
工具
服务